Table 3.
Relationship of 15-PGDH expression in NACT group and clinicopathologic parameters
| Low-15-PGDH expression n=8 | High-15-PGDH expression n=48 | P-value | |
|---|---|---|---|
| Gender | |||
| Male | 8 (18.2%) | 36 (81.8%) | 0.111 |
| Female | 0 (0.0%) | 12 (100.0%) | |
| Age | |||
| <55 | 4 (15.4%) | 22 (84.6%) | 0.827 |
| ≥55 | 4 (13.3%) | 26 (86.7%) | |
| Differentiation | |||
| well-moderately | 0 (0.0%) | 20 (100.0%) | 0.023 |
| Poorly | 8 (22.2%) | 28 (77.8%) | |
| Invasion depth | |||
| T2 | 0 (0.0%) | 9 (100.0%) | 0.181 |
| T3/T4 | 8 (17.0%) | 39 (83.0%) | |
| TNM stage | |||
| I+II | 0 (0.0%) | 22 (100.0%) | 0.014 |
| III+IV | 8 (23.5%) | 26 (76.5%) | |
| Lymph node metastasis | |||
| No | 1 (4.8%) | 20 (95.2%) | 0.016 |
| Yes | 7 (20.0%) | 28 (80.0%) |
T2, tumour invasion of the muscularis propria or subserosa; T3, tumour invasion extends to or beyond the serosa; T4, tumour invasion of adjacent structures; well-moderately: well-moderately differentiated carcinoma; Poorly: poorly differentiated carcinoma.